Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
RPRX
#573
Royalty Pharma plc Class A Ordinary Shares
48.820
0
USD
+0.81%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.81%
Monthly Change
+6.52%
6 month change
+31.03%
Year Change
+31.03%
Previous Close
48.430
0
Open
48.820
0
Bid
Ask
Low
48.820
0
High
48.820
0
Volume
203
Markets
US Stock Market
Healthcare
RPRX
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
388.13 M
432.96 M
443.17 M
446.69 M
433.32 M
428.42 M
—
Valuation ratios
Enterprise value
29.42 B
27.35 B
25.83 B
21.89 B
20.17 B
27.82 B
100.77 B
Price to earnings ratio
31.16
39.04
394
11.17
13.36
21.71
70.31
Price to sales ratio
8.85
7.22
7.71
7.24
6.7
9.17
34.98
Price to cash flow ratio
9.24
8.19
8.05
5.7
5.47
8.76
32.76
Price to book ratio
6.31
4.19
3.07
2.61
2.18
3.37
5.6
Enterprise value to EBITDA ratio
168.52 K
113.31 K
577.4 K
109.36 K
120.6 K
150.62 K
509.31 K
Profitability ratios
Return on assets %
0.06
0.04
0
0.07
0.05
0.04
0.04
Return on equity %
0.1
0.06
0
0.11
0.08
0.08
0.08
Return on invested capital %
45.75
39.11
7.99
38.15
30.83
34.06
34.9
Gross margin %
92.64
100.56
68.24
75.24
63.21
111.34
447.42
Operating margin %
75.17
62.49
13.73
63.37
57.1
65.58
262.81
EBITDA margin %
84.97
93.29
18.52
65.6
53.88
62.24
248.14
Net margin %
45.94
27.07
1.91
48.2
37.95
32.42
128.9
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
8.76
16.81
2.19
7.9
1.44
2.4
8.7
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.13
0.14
0.13
0.14
0.13
0.13
0.13
Solvency ratios
Debt to assets ratio
0.36
0.41
0.36
0.37
0.36
0.44
1.64
Debt to equity ratio
1.21
1.23
1.09
0.94
0.95
1.33
4.76
Long term debt to total assets ratio
0.36
0.41
0.36
0.37
0.36
0.44
1.64
Long term debt to total equity ratio
1.21
1.23
1.09
0.94
0.95
1.32
4.75
Per share metrics
Operating cash flow per share
3.35
3.32
4.9
4.96
4.66
4.41
4.4
EBIT per share
2.63
2.36
0.7
2.47
2.18
2.76
2.75
EBITDA per share
2.97
3.52
0.95
2.56
2.05
2.62
2.63
Total debt per share
9.58
11.69
13.97
10.18
11.13
15.22
54.5
Cash per share
3.4
3.61
3.96
0.82
1.66
1.13
5.89
Net current asset value per share
4.44
4.74
5.83
2.11
3.03
2.71
11.9
Tangible book value per share
12.76
13.91
12.85
10.83
11.69
9.84
40.86
Working capital per share
3.94
4.46
3.17
1.85
0.92
1.58
5.64
Book value per share
7.94
9.51
12.85
10.83
11.69
11.47
45.8
News
Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive?
Revolution Medicines: PDAC Data Wows Wall Street - Jury's Out On Further Upside (RVMD)
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report?
Why Is Apellis Pharmaceuticals (APLS) Down 17.3% Since Last Earnings Report?
Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report?
Defense Lifts Moat Stocks As Tech Stumbles
Royalty Pharma at TD Cowen Conference: Strategic Growth Insights
Citizens reiterates Zymeworks stock rating on strong cash position
Royalty Pharma appoints Kenneth Sun to lead Asia expansion
Zymeworks secures $250M royalty financing from Royalty Pharma
TD Cowen raises Royalty Pharma stock price target to $50 on growth